Professor Michael Hofman is a nuclear medicine physician at the Centre for Molecular Imaging, Cancer Imaging at the Peter MacCallum Cancer Centre in Melbourne, Australia's only public hospital dedicated to cancer treatment, research and education. He previously completed a fellowship at Guy's & St Thomas' in London, and was a consultant at Monash Health and MIA. He has a broad interest in positron emission tomography (PET), molecular imaging applications in oncology and theranostics (radionuclide therapy). He has a vision of improving patient outcomes by using molecular imaging to non-invasively characterise disease enabling improved selection of the most appropriate therapy for an individual patient and better assessment of therapeutic response. He has particular interest in novel F-18 and Ga-68 PET radiotracers, and theranostic applications including prostate and neuroendocrine tumours. As a scientific committee member of Australasian Radiopharmaceutical Trials Network (ARTnet) he supports the development of high-quality clinical trials. He is currently the principal investigator of the proPSMA multi-centre randomised trial of PSMA PET for staging prostate cancer, and the TheraP multi-centre randomised trial of Lu-177 PSMA therapy. He has authored over 100 peer-reviewed articles and several book chapters. He is currently an Associate Editor for several journals including Cancer Imaging, Leukaemia Lymphoma, and the Journal of Medical Imaging and Radiation Oncology (JMIRO), and is the Vice-Chairperson of the Oncology Scientific Committee for the Society of Nuclear Medicine and Molecular Imaging.